

Alkermes plc. (ALKS)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001520262

Alkermes plc. ALKS; healthcare	
Grade	A ▼ A B C D E strongest fifth of 371 graded peers percentile 8.6; sampling error 2.5 points; lower is stronger
Rank	33 of 371
Profitability	B + + + + + percentile 31.5
Solvency	B + + + + + percentile 33.5
Growth and financing	B + + + + + percentile 33.8
Reliability	0.91 AUC filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$591M to \$2.67B assets total assets \$2.5B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: distress
Inputs computable	9 of 14
Graded from	filings received through Feb 25, 2026 226 days before the rescan; latest periodic filing 10-Q received Jul 28, 2026
Last close	\$40.11 2026-10-08; market equity \$6.7B
Price used in grade	None



A, the bull

strongest fifth of its sector;
letters are fifths of the 371
graded peers

Share price, twelve months to the rescan


split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: C/D from Sep 21, 2023, D from Oct 21, 2023, C/D from Nov 21, 2023, A from Feb 25, 2026

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 25, 2026

" in this Annual Report. If we are unable to compete successfully in the highly competitive biopharmaceutical industry, our business, financial condition, cash flows and results of operations could be materially adversely affected. Our revenues from sales of our products may decrease or grow at a slower than expected rate due to many factors. We cannot be assured that our products will be, or will continue to be, accepted in the U.S. or markets outside the U.S. or that we will be able to maintain or increase sales of our

products.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 31.5						
Gross profitability		51.4%	32.2%	22.1	372	2025-12-31
Return on invested capital		not computable	9.3%			latest aligned inputs end 2016-12-31; latest annual assets end 2025-12-31
Accruals ratio		(12.3%)	(6.6%)	35.6	811	2025-12-31
Gross margin stability, five years		2.1 pts	2.8 pts	36.8	243	2025-12-31
Solvency, sleeve percentile 33.5						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		6.24	(0.31)	15.5	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		3.55x	2.96x	51.4	839	2025-12-31
Growth and financing, sleeve percentile 33.8						
Revenue growth, three-year compound		9.9%	10.0%	51.0	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		213.1%	37.1%	15.5	104	2025-12-31
Asset growth, three years		8.2%	2.1%	34.1	704	2025-12-31
Net share issuance, one year		2.5%	2.5%	34.8	634	2026-02-20

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
28	iRhythm Holdings, Inc. (IRTC)	7.3	A	fortress balance sheet
29	Globus Medical Inc. (GMED)	7.6	A	
30	Hims & Hers Health, Inc. (HIMS)	7.8	A	
31	Gyre Therapeutics, Inc. (GYRE)	8.1	A	fortress balance sheet
32	Veracyte, Inc. (VCYT)	8.4	A	
33	Alkermes plc. (ALKS) <	8.6	A	
34	Si-Bone, Inc. (SIBN)	8.9	A	fortress balance sheet
35	Viridian Therapeutics, Inc.\DE (VRDN)	9.2	A	dilution, fortress balance sheet
36	Xtant Medical Holdings, Inc. (XTNT)	9.5	A	fortress balance sheet
37	Viemed Healthcare, Inc. (VMD)	9.7	A	
38	LivaNova plc (LIVN)	10.0	A	fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	56.6%	8.0%	80
Distance from 52-week high	(27.4%)	(31.4%)	56
EBIT to enterprise value	3.3%	(1.5%)	67
Free cash flow yield	7.1%	(1.0%)	87
Book value to price	0.27	0.28	48
Sales to price	0.22	0.31	40
Composite equity issuance, five years	5.2%	20.3%	33
Relative strength against the sector, log excess return	0.24	(0.14)	80

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail

Cash, filings, liquidity							
Cash and equivalents							\$511.5M
Operating cash flow, four quarters							\$251.2M
Months of runway							not finite
Days since last periodic filing						73 (10-Q received Jul 28, 2026)	
Median daily dollar volume, 63 sessions							\$77.5M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.5B	2025-12-31	2026-02-25	10-K	0001193125-26-068925
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$196.5M	2025-12-31	2026-02-25	10-K	0001193125-26-068925
3	assets	us-gaap:Assets	\$2.5B	2025-12-31	2026-02-25	10-K	0001193125-26-068925
4	operating income	us-gaap:OperatingIncomeLoss	-\$208.7M	2016-12-31	2019-02-15	10-K	0001564590-19-003060
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndLossFromEquityMethodInvestments	\$314.4M	2025-12-31	2026-02-25	10-K	0001564590-19-003060
6	income tax	us-gaap:IncomeTaxExpenseBenefit	-\$5.9M	2016-12-31	2019-02-15	10-K	0001564590-19-003060
7	total debt	us-gaap:LongTermDebt	\$283.7M	2016-12-31	2017-02-17	10-K	0001520262-17-000007
8	book equity	us-gaap:StockholdersEquity	\$1.2B	2016-12-31	2020-02-13	10-K	0001564590-20-004489
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$186.4M	2016-12-31	2018-02-16	10-K	0001520262-18-000016
10	total debt	us-gaap:LongTermDebt	\$349.9M	2015-12-31	2017-02-17	10-K	0001520262-17-000007
11	book equity	us-gaap:StockholdersEquity	\$1.3B	2015-12-31	2019-02-15	10-K	0001564590-19-003060
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$181.1M	2015-12-31	2018-02-16	10-K	0001520262-18-000016
13	net income	us-gaap:NetIncomeLoss	\$241.7M	2025-12-31	2026-02-25	10-K	0001193125-26-068925
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$520.8M	2025-12-31	2026-02-25	10-K	0001193125-26-068925
15	assets	us-gaap:Assets	\$2.1B	2024-12-31	2026-02-25	10-K	0001193125-26-068925
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.6B	2024-12-31	2026-02-25	10-K	0001193125-26-068925
17	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$245.3M	2024-12-31	2026-02-25	10-K	0001193125-26-068925
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.7B	2023-12-31	2026-02-25	10-K	0001193125-26-068925
19	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$253.0M	2023-12-31	2026-02-25	10-K	0001193125-26-068925
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.1B	2022-12-31	2025-02-12	10-K	0000950170-25-019011
21	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$218.1M	2022-12-31	2025-02-12	10-K	0000950170-25-019011
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.2B	2021-12-31	2024-02-21	10-K	0000950170-24-017883
23	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$197.3M	2021-12-31	2024-02-21	10-K	0000950170-24-017883
24	current assets	us-gaap:AssetsCurrent	\$1.9B	2025-12-31	2026-02-25	10-K	0001193125-26-068925
25	current liabilities	us-gaap:LiabilitiesCurrent	\$543.4M	2025-12-31	2026-02-25	10-K	0001193125-26-068925
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$734.8M	2025-12-31	2026-02-25	10-K	0001193125-26-068925
27	operating income	us-gaap:OperatingIncomeLoss	\$254.0M	2025-12-31	2026-02-25	10-K	0001193125-26-068925
28	book equity	us-gaap:StockholdersEquity	\$1.8B	2025-12-31	2026-02-25	10-K	0001193125-26-068925
29	liabilities	us-gaap:Liabilities	\$667.7M	2025-12-31	2026-02-25	10-K	0001193125-26-068925
30	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$94.3M	2016-12-31	2019-02-15	10-K	0001564590-19-003060
31	operating income	us-gaap:OperatingIncomeLoss	\$414.1M	2023-12-31	2026-02-25	10-K	0001193125-26-068925
32	interest expense	us-gaap:InterestExpense	\$23.0M	2023-12-31	2024-02-21	10-K	0000950170-24-017883
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$40.4M	2025-12-31	2026-02-25	10-K	0001193125-26-068925
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$439.1M	2024-12-31	2026-02-25	10-K	0001193125-26-068925
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$33.5M	2024-12-31	2026-02-25	10-K	0001193125-26-068925
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$401.4M	2023-12-31	2026-02-25	10-K	0001193125-26-068925
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$48.0M	2023-12-31	2026-02-25	10-K	0001193125-26-068925
38	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$21.0M	2022-12-31	2025-02-12	10-K	0000950170-25-019011
39	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$38.3M	2022-12-31	2025-02-12	10-K	0000950170-25-019011
40	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$27.2M	2025-12-31	2026-02-25	10-K	0001193125-26-068925
41	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinary Items Nondeductible Losses	\$291.4M	2025-12-31	2026-02-25	10-K	0001193125-26-068925
42	income tax	us-gaap:IncomeTaxExpenseBenefit	\$49.8M	2025-12-31	2026-02-25	10-K	0001193125-26-068925
43	current assets	us-gaap:AssetsCurrent	\$1.4B	2024-12-31	2026-02-25	10-K	0001193125-26-068925
44	current liabilities	us-gaap:LiabilitiesCurrent	\$465.2M	2024-12-31	2026-02-25	10-K	0001193125-26-068925
45	assets	us-gaap:Assets	\$2.1B	2023-12-31	2025-02-12	10-K	0000950170-25-019011
46	assets	us-gaap:Assets	\$2.0B	2022-12-31	2024-02-21	10-K	0000950170-24-017883
47	shares outstanding	dei:EntityCommonStockSharesOutstanding	166,649,934	2026-02-20	2026-02-25	10-K	0001193125-26-068925
48	shares outstanding	dei:EntityCommonStockSharesOutstanding	162,614,067	2025-02-07	2025-02-12	10-K	0000950170-25-019011